Clinical scenarios demonstrating value of NGS for oncology biomarker testing of tissue and liquid specimens

When choosing the optimal NGS approach for biomarker testing, there are a wide variety of factors to consider for successful delivery of results. The optimal specimen type (tissue and plasma) and sequencing approach (rapid targeted panel and comprehensive) needs to be considered for each patient case across cancer types. The audience will participate in a discussion with an expert on clinical scenarios that can impact NGS success rate and selection of the best specimen and NGS approach including:

• Limited tissue or DNA/RNA input
• Aggressiveness of patient’s disease
• Determining clinical trial eligibility
• Detection of gene signatures (i.e., TMB) & rare variants

Karina Eterovic, MSc, PhD
Director, Oncology Diagnostics R&D
Eurofins-Viracor Clinical Diagnostics